Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Medtech 2015 in Review

EP Vantage Medtech 2016 in Review EP Vantage Medtech 2016 in Review EP Vantage Medtech 2016 in Review

Download Report

EP Vantage Medtech 2015 in Review

Download Medtech 2015 in Review, the new report from our editorial team EP Vantage, which shows that total value of mergers and acquisitions in the medtech sector in 2015 reached an unprecedented high; a figure that held true even if the record breaking acquisition of Covidien by Medtronic was excluded.

This report is released in conjunction with EP Vantage Pharma and Biotech 2015 in Review; both reports offer analysis and expert commentary on M&A deals, venture financing, initial public offerings and FDA approvals in the pharma and medtech sector in 2015.

Key Highlights in Medtech 2015 in Review:

  • Total M&A value in 2015 in the medtech sector reached an unprecedented high
  • Questions remain about how the medtech sector can stimulate investing and deals for emerging to mid-size companies, to support sector innovation and growth
  • A total of 51 novel medical devices were approved by the FDA in 2015, the most in a decade

Press Release

Confirm your details on form below to download this report